What is Avalo Therapeutics's change in accrued liabilities?

Avalo Therapeutics (AVTX) reported change in accrued liabilities of -$1.5M in Q1 2026.

How has Avalo Therapeutics's change in accrued liabilities changed year-over-year?

Avalo Therapeutics's change in accrued liabilities increased by 12.1% year-over-year, from -$1.7M to -$1.5M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Avalo Therapeutics AVTX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

XencorXNCR

-$707K+77.6%

Vera TherapeuticsVERA

-$437K+90.9%

ImmunityBio, Inc.IBRX

$3.14M+124%

Kymera TherapeuticsKYMR

-$7.21M+38.3%

Alumis Inc.ALMS

-$9.72M-295%

Apogee Therapeutics, Inc.APGE

$4.67M+77.0%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's change in accrued liabilities?: Avalo Therapeutics (AVTX) reported change in accrued liabilities of -$1.5M in Q1 2026.
How has Avalo Therapeutics's change in accrued liabilities changed year-over-year?: Avalo Therapeutics's change in accrued liabilities increased by 12.1% year-over-year, from -$1.7M to -$1.5M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.